Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pharmacokinetic Evaluations of Tabalumab Following Subcutaneous Administration by Prefilled Syringe or Auto Injector in Patients With Systemic Lupus Erythematosus

Next Previous
Trial Profile

Pharmacokinetic Evaluations of Tabalumab Following Subcutaneous Administration by Prefilled Syringe or Auto Injector in Patients With Systemic Lupus Erythematosus

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 18 Jun 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tabalumab (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Pharmacokinetics; Registrational
  • Sponsors Eli Lilly and Company

Most Recent Events

  • 08 Apr 2016 Status changed from completed to discontinued.
  • 06 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
  • 25 Nov 2014 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top